|
|
|
|
| Developing and expanding multi-particulate systems presents complex formulation and manufacturing challenges, particularly in polymer selection, to achieve the desired release profiles. Consequently, success requires meticulous planning to mitigate scaleup, filling, and transfer risks whether launching a new drug or adapting an existing therapy into a new dosage form. Click here to learn more. |
|
|
|
| Segments: Next-Generation Tablet Press Technology | Article | By Todd Martin, Natoli Engineering Company, Inc. | Segments increase press output by up to 25% and cut setup time by 88%. Learn the benefits, drawbacks, and manufacturing needs of this rapidly growing tablet press technology. |
|
|
| Producing Quality APIs At Scale | Case Study | Grace Fine Chemical Manufacturing Services | Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Through more than a dozen editorials starting in February of 2024, Chief Editor Louis Garguilo has disagreed a most reliable, trusted, and thus utilized global CDMO deserves to be brandished as off-limits to U.S. drug sponsors. Here we are again: WuXi AppTec is included in the Pentagon’s new list of companies said to have ties to the Chinese government and military. Here is Garguilo's update. | |
|
|
May 2026 — CDMO Opportunities And Threats Report | By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| How The '3S's' Determine Development Success | Webinar | Thermo Fisher Scientific | Gain actionable insights into how a proactive 3S approach can reduce development risks, streamline scale-up, and position your drug product for a smoother path to commercialization. |
|
|
| Sustainability In Small Molecule API Manufacturing | White Paper | MilliporeSigma | Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing. |
|
|
| Contract Pharma 2026: CDMO Collaboration | Article | Mikart | An overview of a milestone pharmaceutical outsourcing conference focused on CDMO collaboration, tech transfer, and oral solid and liquid dose manufacturing strategies. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
